Boehringer Ingelheim
This website is for UK Healthcare Professionals. If you are a patient or member of the public please visit our public website here
Find adverse event reporting information at the bottom of this page
Contact
Boeringer Ingelheim Logo
Boeringer Ingelheim
Boeringer Ingelheim Logo
Boeringer Ingelheim
Boeringer Ingelheim Logo
Boeringer Ingelheim
  • Diseases
    Diseases

    • Diseases
    • Asthma
    • Chronic Heart Failure (CHF) Opens in new tab
    • Chronic Kidney Disease (CKD) Opens in new tab
    • COPD
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Progressive Pulmonary Fibrosis (PPF)
    • Stroke
    • Type 2 Diabetes
  • Products
    Products

    • Products
    • Empagliflozin
    • Linagliptin
    • METALYSE 25 mg (tenecteplase)
    • OFEV® (nintedanib)
    • SPIOLTO® Respimat® (tiotropium/olodaterol)
    • SPIRIVA® Respimat® (tiotropium)
  • Resources
    Resources

    • Resources
      • Healthcare Professional Resources
      • Cardio Renal Metabolism
      • Respiratory
  • Click here to join
    our mailing list to hear
    news & updates about our products     Opens in new tab
  • Find adverse event reporting information at the bottom of this page
  • Contact
Boeringer Ingelheim
Metalyse® 25mg (tenecteplase) logo
Metalyse® 25 mg (tenecteplase) packshot

Join Our Mailing List

 Opens in new tab

Prescribing Information

 Opens in new tab

Metalyse® 25 mg (TENECTEPLASE) is available for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage1

Because Every 
Minute Matters

HRCT
  • Metalyse 25 mg for AIS
  • ThiNK Stroke
  • Clinical Trial Data
  • Dosing & Administration
  • Contraindications
  • Time is Brain
  • Resources

Clinical Tools, Training & Support

Acute ischaemic stroke: Assessment and management pack

Click to view an online document which contains information on stroke assessment and managing stroke patients. This includes the Glasgow Coma Scale, National Institutes of Health Stroke Scales, the dosing table and clinical particulars for Metalyse 25 mg in suitable AIS patients and an overview of immediate post-stroke management.

View content
Acute ischaemic stroke: Assessment and management pack

Thrombolysis: evidence in focus

Click to view common perceptions around thrombolysis in AIS, and how the evidence challenges them.

View content
Thrombolysis: evidence in focus

View related resources

Learn more
Real‑World Guidance from Clinicians

Real‑World Guidance from Clinicians

Learn more
Learn more
How to reconstitute Metalyse 25 mg

How to reconstitute Metalyse 25 mg

Learn more
Back to Metalyse Homepage

Reference

  1. Metalyse 25 mg (tenecteplase) Summary of Product Characteristics.

PC-GB-112309 April 2026

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

  1. Home
  2. Products
  3. Metalyse® 25 mg (tenecteplase) for AIS
  4. Resources
  5. Clinical Tools, Training & Support
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Sitemap
  • Terms of Use
  • Accessibility Statement
Boehringer Ingelheim Logo
Boehringer Ingelheim

This information is for UK Healthcare Professionals only. Products discussed herein may have different labelling in different countries. 
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice.

Copyright © 2021-2026 Boehringer Ingelheim, Inc. All rights reserved. PC-GB-110791 V3 May 2026.